Podcast Pearls
Experts Answer Questions on Current and Emerging Options for Hemophilia A Management

Download this PDF summary transcript of experts’ answers to questions posed during a live symposium on hemophilia A management.
Miguel A. Escobar, MD
Mark Reding, MD
Guy A. Young, MD
Format: Adobe Acrobat (.pdf)
File Size: 211 KB
Released: January 18, 2022

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Genentech, a member of the Roche Group
Sanofi Genzyme
Takeda Pharmaceuticals U.S.A., Inc.: Takeda Oncology Company

Information on this Educational Activity

Faculty

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Miguel A. Escobar, MD, has disclosed that he has received funds for research support from CSL Behring, Genentech, Novo Nordisk, Sanofi, Takeda, and UniQure (paid to institution) and consulting fees from CSL Behring, BioMarin, Genentech/Roche, HEMA Biologics , Kedrion, NHF, Novo Nordisk, Pfizer, Sanofi, and Takeda.
Mark Reding, MD

Professor of Medicine
Division of Hematology, Oncology and Transplantation
Director, Center for Bleeding and Clotting Disorders
University of Minnesota
Minneapolis, Minnesota

Mark Reding, MD, has disclosed that he has received consulting fees from Bayer, CSL Behring, Novo Nordisk, Sanofi Genzyme, and Takeda; funds for research support from Bayer and Biomarin; and fees for non-CME/CE services from Bayer, CSL Behring, Sanofi Genzyme, and Takeda.
Guy A. Young, MD

Professor of Pediatrics
Director,
Hemostasis and Thrombosis Center
Children's Hospital Los Angeles
University of Southern California Keck School of Medicine
Los Angeles, California

Guy A. Young, MD, has disclosed that he has received funds for research support from Genentech/Roche; fees for non-CME/CE services from Bioverativ, Genentech/Roche, and Sanofi; and consulting fees from CSL-Behring, Genentech/Roche, Grifols, Hema Biologics, Kedrion, Novo Nordisk, Sanofi, Spark, and Takeda.

Program Medium

This program has been made available online.

Related Content

Downloadable resource from Clinical Care Options (CCO) to share with patients that covers the basics of hemophilia A and differences between available prophylaxis therapies

Glaivy Batsuli, MD Released: May 9, 2022

GVHD experts address key questions about the treatment of patients with graft versus host disease in this commentary from Clinical Care Options (CCO)

Corey Cutler, MD, MPH, FRCPC Released: May 4, 2022

From Clinical Care Options (CCO), video webinar on recent advances in management of acute and chronic GVHD for physicians, nurses, and pharmacists

Corey Cutler, MD, MPH, FRCPC David Miklos, MD, PhD Robert Zeiser, MD Physicians: maximum of 1.5 AMA PRA Category 1 Credits Released: May 4, 2022 Expired: May 3, 2023

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the management of hemophilia A with nonfactor replacement therapies

person default Kayla Douglas, PharmD Released: April 27, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings